ReviewNature reviews. Disease primers2025
Vitiligo.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Hair Follicle Stem Cells: Emerging Physiology and Therapeutic Applications.Stem cell reviews and reports · 2026Review
- [Cutaneous presentation of digestive tract disorders and liver disease].Dermatologie (Heidelberg, Germany) · 2026Review
- Tinosporide promotes melanogenesis via activation of cAMP/PKA/CREB-MITF signaling in B16F10 and SK-MEL-2 cells.Journal of natural medicines · 2026Article
- Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.Current opinion in pediatrics · 2026Review
- Molecular Pathogenesis of Vitiligo: Emerging Roles of Epigenetic Regulation.Biomolecules & therapeutics · 2026Review
- Review
- Emerging Perspectives in Vitiligo: Pathogenesis, Treatment, and Biomarker Development.Indian dermatology online journal · 2026Article
- Segmental Vitiligo and Somatic Mosaicism: From Pathogenesis to Therapeutics.Annals of dermatology · 2026Review
- Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation.Clinical reviews in allergy & immunology · 2026Review
- Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.Dermatology and therapy · 2026Article
- Lactate Enhances CD8International journal of molecular sciences · 2026Article
- Review
- A pragmatic roadmap toward personalized vitiligo care.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases.Biomedicines · 2026Review
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.Frontiers in immunology · 2026Review
- Oral Ivarmacitinib for Stable Vitiligo: Preliminary Observations from a Three-Patient Case Series.Clinical, cosmetic and investigational dermatology · 2026Article
- Gut and skin microbiome-metabolome pathways in vitiligo: from dysbiosis to immune activation and melanocyte dysfunction.Frontiers in immunology · 2026Review
- Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances.Clinical, cosmetic and investigational dermatology · 2026Review
- Regulatory T cells in vitiligo: a review of functional disequilibrium between peripheral blood and lesional tissue.Frontiers in immunology · 2026Review
- Bioinformatics analysis reveals the characteristics of immune microenvironment in major depressive disorder and vitiligo.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is an acquired autoimmune depigmenting disorder that affects approximately 0.36% of the global population and presents in three forms based on lesion distribution: non-segmental, segmental and mixed vitiligo. Beyond its visible impact on the skin, vitiligo deeply affects mental well-being and quality of life. The pathogenesis of non-segmental vitiligo is influenced by genetic polymorphisms that are linked to immune response and melanogenesis pathways, whereas environmental factors contribute to disease onset. Diagnosis is generally clinical, with laboratory tests or biopsies rarely required. Melanocyte loss involves mechanisms, such as cellular stress, innate immune activation and adaptive immune responses, that specifically target melanocytes, with a central role for tissue-resident memory T cells. This cascade ultimately leads to the depletion of epidermal melanocytes and impairs melanocyte stem cell regeneration. Clinical management emphasizes shared decision-making with three primary objectives: halting depigmentation, initiating repigmentation and sustaining pigment restoration. Signs of active disease help clinicians to identify patients in need of intervention. Treatments approved in the past 2 years offer potential for reversing disease progression, and emerging therapies targeting key pathways to modulate immune activation and stimulate melanocyte regeneration and differentiation are being tested in clinical trials.
Indexed as
Identifiers
41345471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.